Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cartesian Therapeutics Inc (RNAC)

Cartesian Therapeutics Inc (RNAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cartesian Therapeutics Inc 7495 New Horizon Way Frederick MD 21703 USA

www.cartesiantherapeutics.com Employees: 66 P: 301-348-8698

Sector:

Medical

Description:

Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with generalized myasthenia gravis. Cartesian Therapeutics, formerly known as Selecta Biosciences Inc., is based in WATERTOWN, Mass.

Key Statistics

Overview:

Market Capitalization, $K 175,787
Enterprise Value, $K -36,823
Shares Outstanding, K 26,004
Annual Sales, $ 38,910 K
Annual Net Income, $ -77,420 K
Last Quarter Sales, $ 450 K
Last Quarter Net Income, $ -35,900 K
EBIT, $ -83,920 K
EBITDA, $ -82,770 K
60-Month Beta 0.36
% of Insider Shareholders 60.30%
% of Institutional Shareholders 86.95%
Float, K 10,324
% Float 39.70%
Short Interest 2,081
Short Float 8.00%
Short Volume Ratio 0.18

Growth:

1-Year Return -63.40%
3-Year Return -80.06%
5-Year Return -92.56%
5-Year Revenue Growth 482.49%
5-Year Earnings Growth 87.75%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.38 on 11/06/25
Next Earnings Date 03/12/26
Earnings Per Share ttm -1.56
EPS Growth vs. Prev Qtr -376.00%
EPS Growth vs. Prev Year -100.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 04/05/24

RNAC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -11.95%
Profit Margin % -198.97%
Debt/Equity 0.00
Price/Sales 4.30
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.38
Interest Coverage -1.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar